Researchers presented pooled Harmony Alliance data at ASH indicating that measurable residual disease (MRD) may serve as a surrogate endpoint to accelerate acute myeloid leukemia (AML) trials. The Harmony analysis of 1,858 patients found MRD status predicted outcomes and could identify effective therapies years before overall survival endpoints mature. Investigators said regulators could consider MRD‑based accelerated approval pathways, which might shorten development timelines by four to five years when validated and accepted.